<DOC>
	<DOCNO>NCT01314105</DOCNO>
	<brief_summary>This phase I , open label dose escalation study investigate addition BIBF 1120 treatment combination carboplatin Pegylated Liposomal Doxorubicin ( PLD ) patient advance , platinum sensitive relapse ovarian cancer , fallopian tube carcinoma primary peritoneal cancer .</brief_summary>
	<brief_title>BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin ( PLD ) Patients With Advanced Ovarian Cancer , Fallopian Tube Carcinoma Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Inclusion criterion : 1 . Female patient , age 18 year old , first , second third relapse histologically ( initial diagnosis ) confirm epithelial ovarian cancer , fallopian tube carcinoma primary peritoneal cancer 2 . Up three line prior chemo ( chemotherapy interval surgery count one line therapy ) , treatment free interval &gt; 6 month ( = time last administration prior anticancer treatment , include chemotherapy , hormonal therapy , radiation therapy , diagnosis progressive disease ) 3 . Platinum base chemo immediately precede line 4 . Eligibility treatment i.v . chemotherapy regimen carboplatin AUC 5 PLD 30 mg/m2 every 4 week 5 . Life expectancy least 3 month 6 . Written inform consent consistent International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) guideline 7 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 or1 8 . Prior treatment angiogenesis inhibitor ( bevacizumab , TKI inhibit VEGFR2 ) allow provide treatment bevacizumab discontinue = 28 day prior start therapy treatment TKI discontinue = 3 month prior start therapy , provide antiangiogenic therapy add one preceding line therapy Exclusion criterion : 1 . Prior chemotherapy doxorubicin ( formulation , liposomal nonliposomal doxorubicin ) . 2 . Any contraindication therapy PLD carboplatin , e.g . history hypersensitivity reaction platinumcontaining compound excipients . 3 . Hypersensitivity active substance excipients BIBF 1120 . 4 . Treatment investigational drug participation another clinical trial test drug within past four week start therapy concomitantly trial ( exception : previous treatment angiogenesis inhibitor , cf . inclusion criterion # 8 ) . 5 . Laboratory value indicate increase risk adverse event . 6 . Major surgery within 4 week prior start study treatment . 7 . Patients surgery plan , e.g . interval debulking surgery . 8 . Clinically relevant nonhealing wound , ulcer ( intestinal tract , skin ) bone fracture . 9 . Clinical symptom sign gastrointestinal obstruction require parenteral nutrition hydration . 10 . Gastrointestinal disorder abnormality would interfere absorption study drug . 11 . History clinical symptom brain metastasis . 12 . Prior thrombosis thromboembolic event presence inherit coagulopathy . 13 . History cerebral vascular accident , transient ischemic attack subarachnoid haemorrhage within past 6 month . 14 . Known inherited acquire bleed disorder . 15 . Significant cardiovascular disease . 16 . Serious infection particular require systemic antibiotic ( antimicrobial , antifungal ) antiviral therapy . 17 . Other malignancy diagnose within past 5 year . 18 . Known serious illness concomitant nononcological disease . 19 . Patients unable comply protocol . 20 . Patients preserve reproductive capacity sexually active unwilling use medically acceptable method contraception . 21 . Pregnancy breast feeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>